Skye Bioscience (SKYE) EBT Margin (2013 - 2014)
Skye Bioscience (SKYE) posted quarterly EBT Margin of 9.92% for Q2 2014, down 1279.0% year-over-year from 0.84% in Q2 2013, and down 49.18% quarter-over-quarter from 6.65% in Q4 2013.
Skye Bioscience (SKYE) EBT Margin (2013 - 2014) Analysis & Trends
Skye Bioscience (SKYE) has reported EBT Margin for 2 consecutive years, with 9.92% the latest figure, recorded in Q2 2014.
- In Q2 2014, EBT Margin fell 1279.0% year-over-year to 9.92%; the TTM figure through Apr 2014 stood at 32.89% (changed N/A YoY), while the FY2013 annual figure was 1.11%, down 3039.0% from the prior year.
- EBT Margin slipped to 9.92% in Q2 2014 per SKYE's latest filing, from 6.65% in the prior quarter.
- Across five years, EBT Margin topped out at 2.87% in Q2 2013 and bottomed at 9.92% in Q2 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2014 | -9.92% |
| Oct 31, 2013 | -6.65% |
| Jul 31, 2013 | -1.65% |
| Apr 30, 2013 | 2.87% |
| Jan 31, 2013 | 0.42% |